Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PLK4 | O00444 | 1/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.33 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.33 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.33 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.33 |
| ▸ | RET | P07949 | 1/20 | 0.33 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.33 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.33 |
| ▸ | MARK3 | P27448 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | AXL | P30530 | 1/20 | 0.33 |
| ▸ | FLT4 | P35916 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.33 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.33 |
| ▸ | CLK2 | P49760 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6635451 | 0.91 | SMN1; SMN2 (0.39) | SMN1; SMN2PLK4AURKAPDPK1DYRK3 | |
| SCHEMBL6337982 | 0.87 | SMN1; SMN2 (0.33) | SMN1; SMN2MAPK1MAPTALDH1A1NR3C1 | |
| SCHEMBL6336604 | 0.86 | SMN1; SMN2 (0.32) | SMN1; SMN2MAPK1MAPTALDH1A1NPSR1 | |
| SCHEMBL6339561 | 0.84 | SMN1; SMN2 (0.36) | SMN1; SMN2MAPK1MAPTALDH1A1LMNA | |
| SCHEMBL6708018 | 0.83 | SMN1; SMN2 (0.42) | SMN1; SMN2PLK4AURKAPDPK1DYRK3 | |
| SCHEMBL6339252 | 0.82 | SMN1; SMN2 (0.34) | SMN1; SMN2MAPK1MAPTALDH1A1NR3C1 | |
| SCHEMBL6633657 | 0.80 | SMN1; SMN2 (0.41) | SMN1; SMN2LMNANR3C1NPSR1RXFP1 | |
| SCHEMBL6636279 | 0.79 | SMN1; SMN2 (0.40) | SMN1; SMN2NR3C1NPSR1MEN1KMT2A | |
| SCHEMBL6339994 | 0.77 | MAPT (0.37) | SMN1; SMN2MAPK1MAPTALDH1A1NR3C1 | |
| SCHEMBL6340791 | 0.77 | SMN1; SMN2 (0.35) | SMN1; SMN2PLK4AURKAPDPK1DYRK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6924283-B2 | 4-thioxo-4,7-dihydro-thieno[2,3-b]pyridine-5-carbothioamides as antiviral agents | PFIZER (US) | 2005-08-02 | — | — | US | claimed |
| EP-1421088-A1 | 4-THIOXO-4,7-DIHYDRO-THIENO 2,3-B]PYRIDINE-5-CARBOTHIOAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2004-05-26 | — | — | EP | claimed |
| US-20030100536-A1 | 4-Thioxo-4,7-dihydro-thieno[2,3-b]pyridine-5-carbothioamides as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2003-05-29 | — | — | US | claimed |
| WO-2003020730-A1 | 4-THIOXO-4,7-DIHYDRO-THIENO[2,3-B]PYRIDINE-5-CARBOTHIOAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2003-03-13 | — | — | WO | claimed |
| WO-2003020728-A1 | 4-THIOXO-4,7-DIHYDRO-THIENO[2,3-b]PYRIDINE-5-CARBOTHIOAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2003-03-13 | — | — | WO | claimed |
| US-6924283-B2 | 4-thioxo-4,7-dihydro-thieno[2,3-b]pyridine-5-carbothioamides as antiviral agents | PFIZER (US) | 2005-08-02 | — | — | US | disclosed |
| EP-1421088-A1 | 4-THIOXO-4,7-DIHYDRO-THIENO 2,3-B]PYRIDINE-5-CARBOTHIOAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2004-05-26 | — | — | EP | disclosed |
| US-20030100536-A1 | 4-Thioxo-4,7-dihydro-thieno[2,3-b]pyridine-5-carbothioamides as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2003-05-29 | — | — | US | disclosed |
| WO-2003020730-A1 | 4-THIOXO-4,7-DIHYDRO-THIENO[2,3-B]PYRIDINE-5-CARBOTHIOAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2003-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100536-A1 | 4-Thioxo-4,7-dihydro-thieno[2,3-b]pyridine-5-carbothioamides as antiviral agents | TPMT, TK1, TYMP | SMN1; SMN2 2850/4885PLK4 2188/4885AURKA 2016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.